IJE Software logoIJEsoft
ServicesPortfolioPricingAboutCase StudyStackNewsBlogPartnerPH NewsMarketsContactGet in touch
← Back to Philippines Business News
Manila Times Business

Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO

First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).With a median follow-up of 19.1 months, 12-month disease-free survival (DFS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) rates were 81.1%, 94.1% and 86.2%, respectively, in 38 evaluable patients.Investigators conclude that efti plus KEYTRUDA® (pembrolizumab) and radiotherapy as ne

Context & Analysis

Soft tissue sarcomas are uncommon tumors that can arise in muscle, fat, nerves, blood vessels and deep skin layers, and their rarity makes treatment decisions complicated. For resectable disease, surgery is central, while radiotherapy may be used around the tumor bed to reduce local risk. The more difficult problem is microscopic disease that may already have spread beyond the visible tumor, leading to recurrence or metastasis. The experiment described in the abstract belongs to a broader push to test whether immune-based drugs, given before surgery, can turn a tumor into a better target for local treatment and leave patients with cleaner long-term disease control.

For Philippine business readers, the relevance is less about one conference abstract and more about the pipeline it points to. Oncology remains one of the fastest-moving areas in healthcare, and any signal that a combination of immunotherapy and radiation can improve care in a hard-to-treat cancer may eventually reshape hospital formularies, specialty pharmacy demand, diagnostic imaging volumes and insurance products. Companies that distribute biologics, manage infusion centers, provide laboratory services or develop digital oncology tools may see shifts in demand if regulators later approve new regimens. Insurers and corporate benefit planners also face cost questions, since novel cancer therapies can be expensive and require prior authorization pathways.

In the Philippines, the practical route from a global trial to a patient’s treatment plan involves multiple gatekeepers. The FDA Philippines would need to assess quality, safety and efficacy before marketing authorization, while hospitals and clinicians weigh local feasibility, adverse-event management and cost. Clinical trial participation also depends on institutional ethics review, pharmacovigilance systems and patient access to follow-up testing. A busy investor should watch for peer-reviewed publication, confirmation in a larger study, regulatory filings in major markets, pricing and reimbursement discussions, and whether the regimen can be delivered outside specialized cancer centers. Early scientific excitement can create value for biotech firms and healthcare providers, but it does not guarantee near-term commercial impact in a market where affordability, logistics and physician education remain as important as the science itself.

Analysis by IJE Software — original commentary on the story above.

This is an excerpt. Read the full article at the original source:

Source: manilatimes.net

More from Manila Times Business

The Eureka Ergonomic Opal Collection Adds Light Oak and Walnut Wood Finishes to Its Executive Standing Desk Line

1h ago

Geekvape launches VPU 2.0 atomisation platform in Dubai

1h ago

Preliminary study finds a clue in the quest to help diagnose CTE in the living

1h ago

Blasts, sirens in Bahrain as Iran announces attack on US base

1h ago

Your Daily Briefing

AI business companion — delivered every morning

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals
Blog Topics
HR & Workforce
Real Estate & Property
News & Markets

1 topic selected